EMA to developers: Drop inhalers on the ground; Bend teams with Catalent for controlled-release tech;

 @DamianFierce: Researchers say a reusable ultrasound pill could replace daily injections for patients with cancer and diabetes. Report | Follow @DamianFierce

> The EMA has an interesting request for makers of drug-delivering inhalers: drop them on the ground. The European regulator wants manufacturers to be sure their techs can withstand the normal wear-and-tear of patient use, which includes accidental drops. More

> Medgenics ($MDGN) has received an Orphan Drug Designation from the FDA for Infradure, its hepatitis D treatment that uses the company's innovative Biopump delivery platform. News

> The CEO and co-founder of drug delivery firm BIND Biosciences received the Ernst & Young New England Entrepreneur of the Year Award. The company, founded by MIT's Robert Langer, is developing targeted, programmable cancer treatments. Item

> Bend Research is partnering with Catalent Pharma Solutions, looking to offer controlled-release drug delivery solutions to developers. Release